Ipca Laboratories Ltd. — Capital/Financing Update 2021

Apr 30, 2021

April 30, 2021

THRU ONLINE FILING

BSE Ltd. Phiroze Jeejeebhoy Towers Dalal Street Mumbai 400 023 Scrip Code - 524494

National Stock Exchange India Limited, Exchange Plaza, C-1, Block-G, Bandra Kurla Complex, Bandra - (East). Mumbai-400051. Scrip Code: IPCALAB

Dear Sirs,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is to inform you that the Company has subscribed to partnership interest in ABCD Technologies LLP (to be renamed as IndoHealth Services LLP).

The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Clause A(1) of Part A, Schedule III of the aforesaid regulations, is attached as per "Annexure A".

This is for your information and dissemination.

Thanking you

Yours faithfully For Ipca Laboratories Limited ~

Harish P. Kamath Corporate Counsel & Company Secretary

Enel: ala

Ipea Laboratories Ltd. www.ipea.com

125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India I T: +91 2262105000 F:+91 2262105005 Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India I T: +91 2266474444 E: ipca@ipca.com ON: L24239MH 1949PLC007837

Annexure A

Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 under Clause A(1) of Part A, Schedule III of the aforesaid regulations on subscription of partnership interest in ABCD Technologies LLP (to be renamed as IndoHealth Services LLP ) by the Company.

a) Name of the target entity, details brief such as size, turnover etc.: b) Whether the acquisition would within related party transactio and whether the promoter/promo group/group companies have interest in the entity being acquir If yes, nature of interest and det thereof and whether the same done at "Arms-length"; c) Industry to which the entity b acquired belongs; d) Objects and effects of acquisi (including but not limited disclosure of reasons for acquisi of target entity, if its business outside the main line of busines the listed entity; e) Brief details of any govemmenta regulatory approvals required for acquisition; f) Indicative time period for comple of the acquisition; g) Nature of consideration - whe cash consideration or share s and details of the same;

in i) Name of the Target entity: ABCD Technologies LLP (to be renamed as IndoHealth Services LLP), herein after referred to as the Target entity. ii) Details of Target entity: The Target entity is a limited liability partnership ('LLP') that has various partners. The Target entity will, through its investment entities, engage in the objective of digitizing healthcare infrastructure in India. fall n(s) ter any ed? ails is eing tion to, tion is s of l or the tion ther wap No. Healthcare services. Initiative with an objective to facilitate, enable and promote efficiency and Good Distribution Practices ('GOP') including digitizing healthcare infrastructure in India, inter alia, in support of the National Digital Health Mission of Government of India ('Business'). None. April 30, 2021. Cash infusion as capital contributbn.

Ipea Laboratories Ltd. www.ipca.com

125,

==> picture [416 x 218] intentionally omitted <==

----- Start of picture text -----

h) Cost of acquisition or the price at Rs. 25 crores.
which the shares are acquired;
i) Percentage of shareholding / control 4.03% share of profit! loss in the Target
acquired and/or number of shares entity.
acquired;
j) Brief background about the entity The Target entity has been incorporated on
acquired in terms of products/line of 10 [th] February, 2021.
business acquired, date of
incorporation, history of last 3 years The Target entity through its investments in
turnover, country in which the OigiHealth Technologies LLP, Pharmarack
acquired entity has presence and Technologies Private Limited, Trikaal
any other significant information (in Mediinfotech Private Limited and AIGCO
brief); Pharmasofttech Awacs Private Limited, aims
to achieve the objectives as per clause (d)
above.
----- End of picture text -----

Ipea Laboratories Ltd. www.ipea.eom

125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India I T: +91 2262105000 F:+91 22 62105005 Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India I T: +91 2266474444 . E: ipca@ipca.com ClN: L24239MH1 949PLC007837